Axon's COVID-19 vaccine shows promise for elderly population

By The Science Advisory Board staff writers

September 10, 2020 -- Clinical-stage biotechnology company Axon Neuroscience has touted results from a preclinical trial for its COVID-19 vaccine candidate.

The ACvac1 vaccine contains key elements of the SARS-CoV-2 spike protein. It is designed to produce an immune response in healthy individuals in order to prevent the novel coronavirus from infecting host cells.

Axon Neuroscience lab technician.
Axon Neuroscience lab technician. Image courtesy of Axon Neuroscience.

In the preclinical trial, mice vaccinated with ACvac1 produced a high titer of serum antibodies against the part of the SARS-CoV-2 spike protein that allows it to infect cells and replicate. The antibodies also effectively neutralized the live novel coronavirus without the mice showing adverse reactions, according to Axon.

The company is now working toward testing the peptide-based vaccine in a clinical trial. The target population is elderly individuals, who often cannot tolerate high vaccine doses due to adverse effects.

The ACvac1 vaccine platform is based on the company's years of research into using immunogenic peptide vaccines for neurodegenerative disorders in patients age 70 or older, Axon noted. The company intends to begin clinical trials as soon as the fourth quarter of 2020.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here